On Tuesday I started the new Clinical Trial. As you may remember the trial consists of two
different arms with one being a pill (the one I thought I wanted) and one being
an infusion. By random draw I got the
infusion. The first infusion is now over, and
I only have 11 more to go. End of short
report.
Before I could begin the trial I had to have a number of tests, sign paperwork, and be 'approved'. All of this was done in the last two weeks. Last Friday I got the word that I was accepted and which arm of the trial I would be in.
Tuesday turned out to be a LONG day. Over 15 hours door to door. I first had lab work, then a doctor’s appointment,
more lab work, the pre-meds, then the infusion.
The total infusion time is about 7 hours. At first I was a little disappointed that I
got the infusion instead of the pill, but after talking to Dr. Kipps, I think
that I will have a good response to this drug.
It is called Ofatumumab, or Azerra.
It is a monoclonal antibody like Rituxan is, but it is a second
generation of the drug. It is approved
for use in CLL so it has been around for a while and even though there are side
effects associated with it, they can be managed. Tuesday I got what they call a TEST
dose. It was only about 1/6 of what I
will get in subsequent doses. They want
to make sure that you don’t have a reaction to the drug and that is why they
give such a small dose and give it over a long period of time. My dose next Tuesday will be 6 times as much
and given over a shorter period of time.
I will get a weekly dose of this for the next 7 weeks and
then I will get a monthly dose for the following 4 months. So the total time will be 6 months. We are not quite sure what happens after
that. There is some talk that the pill
drug might be made available to those patients that need it. Obviously if all my counts, scans and
physical exams show I am back to normal there would be no need for the
drug. But if at some time in the future
I would relapse, I may be first in line to get the pill drug, called
Ibrutinib. The main goal here is to buy
me some more time and not burn any bridges for future treatments. I think the Ofatumumab will accomplish this.
I have had very little side effects from the test dose and
the nurses all expected that because of my past experiences with Rituxan I
wouldn’t have very many with the Ofatumumab either. The measure of how well I am doing can’t be
really verified until another CT scan and a bone marrow biopsy. But I think they will know in a few weeks if
I am responding.
Thanks for all the well wishes and prayers, they are
uplifting.
Terry